Arch. Dis. Child

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
Archives of Disease in Childhood - Education and Practice 2008;93:58-65; doi:10.1136/adc.2006.106864
Copyright © 2008 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in ADC Online
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Harpin, V A
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harpin, V A

PHARMACY UPDATE

Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006

V A Harpin

Correspondence to:
Valerie A Harpin, Ryegate Childrens Centre, Sheffield Children’s NHS Foundation Trust, Tapton Crescent Road, Sheffield S10 5DD, UK; val.harpin{at}sch.nhs.uk

In recent years the medication options for the treatment of ADHD in children and young people have increased. The National Institute for Health and Clinical Excellence (NICE) produced updated guidelines in 2006. This paper aims to interpret these guidelines by reviewing the medication options in light of relevant research and clinical practice. The properties of methylphenidate, dexamfetamine and atomoxetine are discussed.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
ARCH DIS CHILD FETAL NEONATAL ED ED PRACTICE
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health